

Confirmed Speakers

Keynote Speaker

In-cell NMR: a Powerful Approach for Drug Discovery (KL01)



Prof. Lucia BANCÌ
(UNIVERSITY OF FLORENCE, Sesto Fiorentino, Italy)

Invited Speakers

Functionalizing Covalent Binders (IL07)

(SANOFI-AVENTIS DEUTSCHLAND GMBH)



Dr Nir LONDON
(THE WEIZMANN INSTITUTE OF SCIENCE, Rehovot, Israel)

Positioning Biophysics on the Drug Discovery Map (IL05)



Dr Christine GENICK
(NOVARTIS PHARMA AG, Basel, Switzerland)

Reactive Fragment Platforms for Covalent Hit ID (IL06)



Dr Emma GRANT
(GLAXOSMITHKLINE, Stevenage, United Kingdom)

Exploration of Orthogonal E3 Ligases for Targeted Protein Degradation (IL10)



Dr Lena MÜNZKER
(BOEHRINGER INGELHEIM, Wien, Austria)

Molecular Glues Stabilizing 14-3-3 Protein-Protein Interactions (IL09)



Dr Christian OTTMANN
(EINDHOVEN UNIVERSITY OF TECHNOLOGY, Eindhoven, The Netherlands)

Manipulating RNA Function by Structural Dynamics (IL02)



Prof. Katja PETZOLD
(KAROLINSKA INSTITUTET, Stockholm, Sweden)

Structure-Based Design of a Phosphotyrosine-Masked, Cell Penetrant Small Molecule Covalently Targeting the E3 Ligase SOCS2 (IL08)



Dr Sarath RAMACHANDRAN
(UNIVERSITY OF DUNDEE, Scotland, United Kingdom)

Confirmed Speakers

In-cell NMR to study RNA Structure and Folding (IL04)



Prof. Harald SCHWALBE
(J.W. GOETHE UNIVERSITY FRANKFURT, Frankfurt am Main, Germany)

Measuring Ligand Binding in Cells Using CETSA® (IL03)



Dr Joseph SHAW
(ASTRAZENECA, Cambridge, United Kingdom)

Fluorescent Nucleobase Analogues - minimally Perturbing Labels in Nucleic Acid Biophysics and Bioimaging as well as Drug Discovery (IL01)



Prof. Marcus WILHELMSSON
(CHALMERS UNIVERSITY OF TECHNOLOGY, Gothenburg, Sweden)

Oral Communications

Binding of Small Molecules to Oligonucleotides in Drug Discovery (OC02)

(SANOFI-AVENTIS DEUTSCHLAND GMBH)



Dr Nina GROSSMANN
(MERCK HEALTHCARE, Darmstadt, Germany)

The Use of Dual Targeted Bicycles® to Induce Localised CD137 Agonism (OC04)



Dr Peter BROWN
(BICYCLE THERAPEUTICS, Cambridge, United Kingdom)

Biophysical Methods Enabling Structure-Based Drug Discovery on Membrane Protein Targets (OC05)



Dr Michael HENNIG
(LEADXP AG, Villigen, Switzerland)

The Biophysics in the Discovery of Potent cGAS Inhibitors (OC08)



Dr Manuel HILBERT
(F. HOFFMANN-LA ROCHE LTD, Basel, Switzerland)

Structure-based Design of RNA-Binding Small Molecules and their Binding Characterization via MST, (kin)ITC and SwitchSENSE Assays (OC01)



Dr Christian KERSTEN
(JOHANNES GUTENBERG UNIVERSITY, Mainz, Germany)

8th NovAliX Conference | Hybrid Event

Confirmed Speakers

Discovery and Characterization of Active Small Molecule Ligands Targeting the Function of Ubiquitin Specific Protease USP7 by a Catalytic Site Independent Mechanism (OC07)



Prof. Till MAURER
(IDEAYA BIOSCIENCES, South San Francisco, United States)

Observing Reversible Engagement of KRAS Hotspot Mutants at the Switch-2 Pocket in Cells (OC03)



Mr Matthew ROBERS
(PROMEGA, Madison, United States)

Applying Biophysical Interaction Methods to Characterize Binary and Ternary Complex Formation (OC06)



Dr Daniel SCHWARZ
(MERCK KGAA, Darmstadt, Germany)

Towards Regulation of MDM2 via Stabilisation of a Complex Protein-Protein Interaction (OC09)



Mr Jake WARD
(UNIVERSITY OF LEICESTER, Leicester, United Kingdom)